The first multiparameter FCM application for neuroblastoma cell detection was based on CD9+/CD56+/CD45– immunophenotype (61), which was later replaced by CD81+/CD56+/CD45– immunophenotype (91). The gene discussed is CD81; the disease is neuroblastoma.